Cardiovascular Diseases

Clinical research at Barmherzige Brueder gemeinnuetzige Traeger GmbH in Straubing includes studies in cardiovascular diseases focused on improving care for people with atrial fibrillation, acute coronary syndrome, myocardial infarction, type 2 diabetes, hypertension, and established cardiovascular disease. These trials are designed to evaluate treatment effectiveness and reduce serious heart-related complications.

  • Optimizing antiplatelet and anticoagulant treatment in patients with atrial fibrillation and acute coronary events
  • Testing a new approach for lowering the risk of cardiovascular death, heart failure hospitalization, or urgent heart care visits

This work reflects a strong focus on better protection against ischemic events, heart failure, and other major cardiovascular outcomes.

Neoplasms

The site is also active in oncology, with trials addressing several neoplasms, including bladder cancer, head and neck squamous cell carcinoma, and chronic lymphocytic leukemia. Research here aims to test new therapies, compare treatment strategies, and improve survival outcomes for patients with difficult-to-treat cancers.

  • Evaluating a targeted bladder cancer treatment for tumors with FGFR gene alterations
  • Studying sequential therapy approaches for locally advanced head and neck cancer
  • Comparing treatment options for previously untreated chronic lymphocytic leukemia

These studies highlight a broad interest in advancing cancer care through more effective and personalized treatment options.

Immune System Processes

Research in immune system processes at this hospital includes trials in psoriasis and psoriatic arthritis, where investigators are examining how well new preventive or supportive approaches are tolerated and how they affect underlying disease activity. The goal is to improve care for chronic inflammatory conditions while maintaining safety.

  • Assessing the safety and immune response of vaccination in patients with psoriasis or psoriatic arthritis

This area of study supports better understanding of immune-related disease management and patient well-being.